NCT02710851进行中（未招募）2 期
A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years
Jun Zhang0 个研究点目标入组 640 人开始时间: 2016年3月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 640
- 主要终点
- Anti-HPV 6 and anti-HPV 11 geometric mean concentrations (type specific IgG antibody)
研究概览
简要总结
This phase Ⅱ clinical study was designed to evaluate the immunogenicity and safety of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged 18-55 years of age at enrollment. The study volunteers would be randomized to receive the 3 different formulations of the novel HPV vaccine or placebo vaccine (recombinant hepatitis E vaccine) administered intramuscularly according to a 0-1-6 month schedule. This is a double-blind study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants aged between 18 and 55 years.
- •Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations.
- •Written informed consent obtained from the participants.
- •Able to comply with the requests of the study.
- •Axillary temperature not higher than 37.0°C
- •Non-pregnancy verified by a urine pregnancy test.
排除标准
- •Pregnant or breastfeeding or plan to be pregnant within 7 months.
- •Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period.
- •Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment.
- •Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine.
- •Administration of any attenuated live vaccines within 30 days preceding the first dose of the study vaccine or any subunit or inactivated vaccines within 14 days before vaccination.
- •Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination.
- •Having the plan to participate another clinical trial during the study period.
- •Received another HPV vaccine.
- •Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, .or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response).
- •History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.
- •Having serious disease of internal medicine, such as hypertension, cardiac disease, diabetes, hyperthyroidism et al.
- •Asthma that required emergent treatment, hospitalization, oral or intravenous corticosteroid for unstable condition within the past 2 years.
- •Diagnosed coagulant function abnormality (i.e., clotting factors absent, clotting hemorrhagic disease, abnormal platelet function) or blood coagulation disorder.
- •Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3 years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3 years.
- •Past or current two-stage affective psychosis, not well controlled in the past 2 years or requiring drugs, or h a tendency to commit suicide.
- •Other medical, psychological, social or occupational factors that, according to the investigators' judgment, might affect the individual's ability to obey the protocol or sign the informed consent.
结局指标
主要结局
Anti-HPV 6 and anti-HPV 11 geometric mean concentrations (type specific IgG antibody)
时间窗: 7 months
Anti-HPV 6 and anti-HPV 11 seroconversion rates (type specific IgG antibody)
时间窗: 7 months
次要结局
- Number of serious adverse events throughout the study(7 months)
研究者
Jun Zhang
Professor
Xiamen University
相似试验
已完成
1 期
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent VaccineCondylomata AcuminataNCT02405520Jun Zhang145
已完成
2 期
Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy AdultsRSV InfectionNCT04752644Bavarian Nordic73
已完成
2 期
Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in TaiwanDengueNCT04133987National Taiwan University Hospital252
已完成
2 期
A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsSmallpoxNCT00857493Bavarian Nordic120
已完成
2 期
Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy AdolescentsTuberculosisNCT02075203Aeras989